Lisanti Capital Growth, LLC Fate Therapeutics Inc Transaction History

Lisanti Capital Growth, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 03, 2021	SELL	$59.27 - $95.73 $7.43 Million - $12 Million	-125,350 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $7.64 Million - $10.5 Million	113,555 Added 962.74%	125,350 $10.9 Million
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $851,127 - $1.38 Million	11,795 New	11,795 $972,000
Q2 2020 Aug 10, 2020	SELL	$20.21 - $35.23 $298,703 - $520,699	-14,780 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$17.28 - $31.88 $255,398 - $471,186	14,780 New	14,780 $328,000

Q4 2019 Feb 13, 2020	SELL	$13.39 - $20.73 $1.67 Million - $2.59 Million	-125,060 Closed	0 $0
Q3 2019 Nov 06, 2019	BUY	$15.47 - $22.5 $981,494 - $1.43 Million	63,445 Added 102.97%	125,060 $1.94 Million
Q2 2019 Aug 05, 2019	SELL	$15.61 - $20.44 $1.83 Million - $2.4 Million	-117,175 Reduced 65.54%	61,615 $1.25 Million
Q1 2019 May 13, 2019	BUY	$13.15 - $18.71 $473,794 - $674,121	36,030 Added 25.24%	178,790 $3.14 Million
Q4 2018 Feb 08, 2019	BUY	$11.48 - $16.98 $1.64 Million - $2.42 Million	142,760 New	142,760 $1.83 Million

178

124M

222K

48.6K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $307M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

Stay updated on Lisanti Capital Growth, LLC with notifications on news.